STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.

MLA

Zhang, Chengfei, et al. “STK39 Is a Novel Kinase Contributing to the Progression of Hepatocellular Carcinoma by the PLK1/ERK Signaling Pathway.” Theranostics, vol. 11, no. 5, Jan. 2021, pp. 2108–22. EBSCOhost, https://doi.org/10.7150/thno.48112.

APA

Zhang, C., Wang, X., Fang, D., Xu, P., Mo, X., Hu, C., Abdelatty, A., Wang, M., Xu, H., Sun, Q., Zhou, G., She, J., Xia, J., Hui, K. M., & Xia, H. (2021). STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway. Theranostics, 11(5), 2108–2122. https://doi.org/10.7150/thno.48112

Chicago

Zhang, Chengfei, Xiaoming Wang, Dan Fang, Ping Xu, Xiao Mo, Chao Hu, Alaa Abdelatty, et al. 2021. “STK39 Is a Novel Kinase Contributing to the Progression of Hepatocellular Carcinoma by the PLK1/ERK Signaling Pathway.” Theranostics 11 (5): 2108–22. doi:10.7150/thno.48112.